tiprankstipranks
Restart Life Sciences (NMLSF)
OTHER OTC:NMLSF
US Market

Restart Life Sciences (NMLSF) Income Statement

Compare
22 Followers

Restart Life Sciences Income Statement

Last quarter (Q3 2024), Restart Life Sciences's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Restart Life Sciences's net income was $459.57K. See Restart Life Sciences’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ ―$ ―$ ―$ ―$ ―
Gross Profit
$ ―$ ―$ ―$ 1.73K$ 1.63K
Operating Expenses
$ ―$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ 2.94K$ 3.79K$ 5.00K$ 6.82K$ 9.80K
EBITDA
$ -1.22M$ -2.46M$ -2.68M$ -1.79M$ -1.39M
Operating Income
$ -1.26M$ -1.94M$ -2.93M$ -1.80M$ -1.22M
Other Income/Expenses
$ ―$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―$ ―
Net Income
$ -1.22M$ -2.47M$ -2.68M$ -25.23M$ -1.40M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ ―$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

Restart Life Sciences Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis